Teva And Royalty Pharma Announce Collaboration To Further Accelerate Olanzapine LAI Program; Royalty To Provide R&D Funding Support Of Up To $125M For Development Of Olanzapine LAI
Portfolio Pulse from Benzinga Newsdesk
Teva Pharmaceutical Industries Ltd. and Royalty Pharma have announced a collaboration to accelerate the development of Olanzapine LAI, a long-acting injectable for schizophrenia treatment. Royalty Pharma will provide up to $125 million in R&D funding support for the program.
November 13, 2023 | 1:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Royalty Pharma's investment in Teva's Olanzapine LAI program represents a strategic move to support the development of a promising schizophrenia treatment.
Royalty Pharma's funding support is a strategic investment in a potential future revenue stream, which could positively impact its earnings if Olanzapine LAI is successful.
CONFIDENCE 80
IMPORTANCE 65
RELEVANCE 70
POSITIVE IMPACT
Teva's collaboration with Royalty Pharma for the Olanzapine LAI program could potentially expedite the drug's development, with financial support of up to $125 million.
The partnership with Royalty Pharma provides Teva with significant R&D funding, which is likely to have a positive impact on the company's financials and its ability to bring Olanzapine LAI to market more quickly.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 80